Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Companyâs lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļKYTX
āļāļ·āđāļāļāļĢāļīāļĐāļąāļKyverna Therapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 08, 2024
āļāļĩāļāļĩāđāļBiddle (Warner Weston)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ112
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļFeb 08
āļāļĩāđāļāļĒāļđāđ5980 Horton Street
āđāļĄāļ·āļāļEMERYVILLE
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ94608
āđāļāļĢāļĻāļąāļāļāđ15106268331
āđāļ§āđāļāđāļāļāđhttps://kyvernatx.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļKYTX
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 08, 2024
āļāļĩāļāļĩāđāļBiddle (Warner Weston)
Dr. Marc Grasso, M.D.
Chief Financial Officer
Ms. Karen Walker
Chief Technology Officer
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Mr. Mert Aktar
Independent Director
Mr. Mert Aktar
Independent Director
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Mr. Mert Aktar
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Marc Grasso, M.D.
Chief Financial Officer
Ms. Karen Walker
Chief Technology Officer
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director